These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 10589154)

  • 1. [Effect of unfractionated and low-molecular-weight heparin on platelet aggregation and in vitro bleeding time in dogs].
    Nimmerfall K; Mischke R
    Dtsch Tierarztl Wochenschr; 1999 Oct; 106(10):439-44. PubMed ID: 10589154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prolonged bleeding time induced by anticoagulant glycosaminoglycans in dogs is associated with the inhibition of thrombin-induced platelet aggregation.
    Kitazato K; Kitazato KT; Sasaki E; Minamiguchi K; Nagase H
    Thromb Res; 2003; 112(1-2):83-91. PubMed ID: 15013278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effect of a high single subcutaneous dose of unfractionated heparin on platelet function in dogs].
    Mischke R; Nimmerfall K
    Berl Munch Tierarztl Wochenschr; 2000 Feb; 113(2):60-4. PubMed ID: 10726363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decreased concentrations of heparinoids are required to inhibit thrombin generation in plasma from newborns and children compared to plasma from adults due to reduced thrombin potential.
    Chan AK; Berry LR; Monagle PT; Andrew M
    Thromb Haemost; 2002 Apr; 87(4):606-13. PubMed ID: 12008942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose response relationships of anticoagulant activities after subcutaneous administration of two low molecular weight heparins in healthy individuals.
    Hellstern P; Kiehl R; von Blohn G; Köhler M; Meierhenrich U; Wenzel E
    Thromb Haemost; 1986 Oct; 56(2):225-8. PubMed ID: 3810557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo effects of a low molecular weight heparin fragment on platelet aggregation and platelet dependent hemostasis in dogs.
    Ljungberg B; Johnsson H
    Thromb Haemost; 1988 Oct; 60(2):232-5. PubMed ID: 2851192
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of subcutaneous injection of unfractionated and low molecular weight heparin on thrombin generation in platelet rich plasma--a study in human volunteers.
    Bendetowicz AV; Kai H; Knebel R; Caplain H; Hemker HC; Lindhout T; Béguin S
    Thromb Haemost; 1994 Nov; 72(5):705-12. PubMed ID: 7900078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of a low molecular weight heparin (Fragmin) and of unfractionated heparin on coagulation activation at the site of plug formation in vivo.
    Eichinger S; Wolz M; Nieszpaur-Los M; Schneider B; Lechner K; Eichler HG; Kyrle PA
    Thromb Haemost; 1994 Dec; 72(6):831-5. PubMed ID: 7740450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heparin-induced thrombocytopenia: a stoichiometry-based model to explain the differing immunogenicities of unfractionated heparin, low-molecular-weight heparin, and fondaparinux in different clinical settings.
    Greinacher A; Alban S; Omer-Adam MA; Weitschies W; Warkentin TE
    Thromb Res; 2008; 122(2):211-20. PubMed ID: 18262226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical evaluation of platelet function analyzer PFA-100 in dogs].
    Keidel A; Mischke R
    Berl Munch Tierarztl Wochenschr; 1998; 111(11-12):452-6. PubMed ID: 9880941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The correlation between plasma anti-factor Xa activity and haemostatic tests in healthy dogs, following the administration of a low molecular weight heparin.
    Mischke R; Grebe S
    Res Vet Sci; 2000 Dec; 69(3):241-7. PubMed ID: 11124095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of unfractionated and low molecular weight heparin on platelet-induced thrombin formation time and platelet adhesion.
    Basic-Micic M; Breddin HK
    Semin Thromb Hemost; 1993; 19 Suppl 1():22-8. PubMed ID: 8395725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of low molecular weight heparins and unfractionated heparin after successive subcutaneous administration. A randomized controlled study in healthy volunteers.
    Pindur G; Heiden M; Köhler M
    Arzneimittelforschung; 1993 May; 43(5):542-7. PubMed ID: 8392345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison between low molecular weight heparin (KABI 2165) and standard heparin in the intravenous treatment of deep venous thrombosis.
    Bratt G; Törnebohm E; Granqvist S; Aberg W; Lockner D
    Thromb Haemost; 1985 Dec; 54(4):813-7. PubMed ID: 3911482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Studies on the neutralizing effects of protamine on unfractionated and low molecular weight heparin (Fragmin) at the site of activation of the coagulation system in man.
    Wolzt M; Weltermann A; Nieszpaur-Los M; Schneider B; Fassolt A; Lechner K; Eichler HG; Kyrle PA
    Thromb Haemost; 1995 Mar; 73(3):439-43. PubMed ID: 7667826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the effects of low molecular weight heparin and unfractionated heparin on activation of human platelets in vitro.
    Westwick J; Scully MF; Poll C; Kakkar VV
    Thromb Res; 1986 May; 42(4):435-47. PubMed ID: 3715810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anticoagulant mechanisms of covalent antithrombin-heparin investigated by thrombelastography. Comparison with unfractionated heparin and low-molecular-weight heparin.
    Atkinson HM; Mewhort-Buist TA; Berry LR; Chan AK
    Thromb Haemost; 2009 Jul; 102(1):62-8. PubMed ID: 19572069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and pharmacodynamics of a low molecular weight heparin (enoxaparin) after subcutaneous injection, comparison with unfractionated heparin--a three way cross over study in human volunteers.
    Bendetowicz AV; Béguin S; Caplain H; Hemker HC
    Thromb Haemost; 1994 Mar; 71(3):305-13. PubMed ID: 8029794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B).
    Mukherjee D; Mahaffey KW; Moliterno DJ; Harrington RA; Yadav JS; Pieper KS; Gallup D; Dyke C; Roe MT; Berdan L; Lauer MS; Mänttäri M; White HD; Califf RM; Topol EJ
    Am Heart J; 2002 Dec; 144(6):995-1002. PubMed ID: 12486423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of oversulfated dermatan sulfate derivatives on platelet aggregation.
    Maaroufi RM; Giordano P; Triadou P; Tapon-Bretaudière J; Dautzenberg MD; Fischer AM
    Thromb Res; 2007; 120(4):615-21. PubMed ID: 17222891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.